Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels

Hepatology

Volumn 50, Issue 5, 2009, Pages 1403-1411

  Haring, Robin ^a   Wallaschofski, Henri ^a   Nauck, Matthias ^a   Dörr, Marcus ^a   Baumeister, Sebastian E ^a   Völzke, Henry ^b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEATH; ECHOGRAPHY; FATTY LIVER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GERMANY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE;

ADULT; AGED; BIOLOGICAL MARKERS; COHORT STUDIES; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS; SEX CHARACTERISTICS;

EID: 72949097025     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23135     Document Type: Article

References (46)

1. Wannamethee G, Ebrahim S, Shaper AG. Gamma-glutamyltransferase:
2. Wannamethee G, Ebrahim S, Shaper AG. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 1995;142:699-708.
3. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005;112:2130-2137.
4. Strasak AM, Kelleher CC, Klenk J, Brant LJ, Ruttmann E, Rapp K, et al. Longitudinal change in serum gamma-glutamyltransferase and cardiovascular disease mortality: a prospective population-based study in 76,113 Austrian adults. Arterioscler Thromb Vasc Biol 2008;28:1857-1865.
5. Nakanishi N, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004;27:1427-1432.
6. Rantala AO, Lilja M, Kauma H, Savolainen MJ, Reunanen A, Kesaniemi YA. Gamma-glutamyl transpeptidase and the metabolic syndrome. J Intern Med 2000;248:230-238.
7. Andre P, Balkau B, Born C, Charles MA, Eschwege E. Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the D.E.S.I.R. cohort. Diabetologia 2006; 49:2599-2603.
8. Lee DH, Jacobs DR Jr, Gross M, Kiefe CI, Roseman J, Lewis CE, et al. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 2003;49:1358-1366.
9. Miura K, Nakagawa H, Nakamura H, Tabata M, Nagase H, Yoshida M, et al. Serum gamma-glutamyl transferase level in predicting hypertension among male drinkers. J Hum Hypertens 1994;8:445-449.
10. Bots ML, Salonen JT, Elwood PC, Nikitin Y, Freire de Concalves A, Inzitari D, et al. Gamma-glutamyltransferase and risk of stroke: the EUROSTROKE project. J Epidemiol Commun Health 2002;56(Suppl 1):i25-i29.
11. Jousilahti P, Rastenyte D, Tuomilehto J. Serum gamma-glutamyl transferase, self-reported alcohol drinking, and the risk of stroke. Stroke 2000; 31:1851-1855.
12. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006;40(Suppl 1):S5-S10.
13. Robinson D, Whitehead TP. Effect of body mass and other factors on serum liver enzyme levels in men attending for well population screening. Ann Clin Biochem 1989;26(Pt 5):393-400.
14. van Barneveld T, Seidell JC, Traag N, Hautvast JG. Fat distribution and gamma-glutamyl transferase in relation to serum lipids and blood pressure in 38-year old Dutch males. Eur J Clin Nutr 1989;43:809-818.
15. Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci 2005;330:326-335.
16. Volzke H, Robinson DM, Kleine V, Deutscher R, Hoffmann W, Ludemann J, et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 2005;11:1848-1853.
17. Volzke H, Schwarz S, Baumeister SE, Wallaschofski H, Schwahn C, Grabe HJ, et al. Menopausal status and hepatic steatosis in a general female population. Gut 2007;56:594-595.
18. Marchesini G, Babini M. Nonalcoholic fatty liver disease and the metabolic syndrome. Minerva Cardioangiol 2006;54:229-239.
19. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007;191:235-240.
20. Haring R, Alte D, Volzke H, Sauer S, Wallaschofski H, John U, et al. Extended recruitment efforts minimize attrition but not necessarily bias. J Clin Epidemiol 2009;62:252-260.
21. John U, Greiner B, Hensel E, Ludemann J, Piek M, Sauer S, et al. Study of Health In Pomerania (SHIP): a health examination survey in an east German region: objectives and design. Sozial Praventivmed 2001;46:186-194.
22. Kawachi I, Kennedy BP. The relationship of income inequality to mortality: does the choice of indicator matter? Soc Sci Med 1997;45:1121-1127.
23. Alte D, Luedemann J, Rose HJ, John U. Laboratory markers carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume are not useful as screening tools for high-risk drinking in the general population: results from the Study of Health in Pomerania (SHIP). Alcohol Clin Exp Res 2004;28:931-940.
24. Luepker R, Evans A, McKeigue P, Reddy KS. Cardiovascular survey methods. Geneva: World Health Organization; 2004.
25. NYHA. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston: Little Brown; 1994:253-255.
26. Groll DL, To T, Bombardier C, Wright JG. The development of a comorbidity index with physical function as the outcome. J Clin Epidemiol 2005;58:595-602.
27. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-117.
28. Dorr M, Wolff B, Robinson DM, John U, Ludemann J, Meng W, et al. The association of thyroid function with cardiac mass and left ventricular hypertrophy. J Clin Endocrinol Metab 2005;90:673-677.
29. Ludemann J, Piek M, Wood WG, Meyer S, Greiner B, John U, et al. [Methods for quality assurance of medical examination in epidemiological field studies: the "Study of Health in Pomerania" (SHIP).] Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes, Germany) 2000;62:234-243.
30. Volzke H, Robinson DM, Schminke U, Ludemann J, Rettig R, Felix SB, et al. Thyroid function and carotid wall thickness. J Clin Endocrinol Metab 2004;89:2145-2149.
31. Volzke H, Schwahn C, Kohlmann T, Kramer A, Robinson DM, John U, et al. Risk factors for goiter in a previously iodine-deficient region. Exp Clin Endocrinol Diabetes 2005;113:507-515.
32. Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH, Boissel JP. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ (Clin Res) 2001;323:75-81.
33. Hosmer D, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. Hoboken, NJ: John Wiley & Sons; 2008.
34. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453-1457.
35. Lee DH, Silventoinen K, Jacobs DR Jr, Jousilahti P, Tuomileto J. gamma-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab 2004;89:5410-5414.
36. Nilssen O, Forde OH. Seven-year longitudinal population study of change in gamma-glutamyltransferase: the Tromso Study. Am J Epidemiol 1994; 139:787-792.
37. Brenner H, Rothenbacher D, Arndt V, Schuberth S, Fraisse E, Fliedner TM. Distribution, determinants, and prognostic value of gamma-glutamyltransferase for all-cause mortality in a cohort of construction workers from southern Germany. Prevent Med 1997;26:305-310.
38. Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007;27:127-133.
39. Lee DH, Jacobs DR Jr. Association between serum gamma-glutamyltransferase and C-reactive protein. Atherosclerosis 2005;178:327-330.
40. Lee DH, Blomhoff R, Jacobs DR Jr. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res 2004;38:535-539.
41. Lim JS, Yang JH, Chun BY, Kam S, Jacobs DR Jr, Lee DH. Is serum gamma-glutamyltransferase inversely associated with serum antioxidants as a marker of oxidative stress? Free Radic Biol Med 2004;37:1018-1023.
42. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-152.
43. Mottin CC, Moretto M, Padoin AV, Swarowsky AM, Toneto MG, Glock L, et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 2004;14:635-637.
44. Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 2001;35:531-537.
45. Makita S, Nakamura M, Satoh K, Tanaka F, Onoda T, Kawamura K, et al. Serum C-reactive protein levels can be used to predict future ischemic stroke and mortality in Japanese men from the general population. Atherosclerosis 2009;204:234-238.
46. Marsik C, Kazemi-Shirazi L, Schickbauer T, Winkler S, Joukhadar C, Wagner OF, et al. C-reactive protein and all-cause mortality in a large hospital-based cohort. Clin Chem 2008;54:343-349.